Immunotherapy

A new Review published in the open-access journal Ferroptosis and Oxidative Stress highlights Z-nucleic acid-binding protein 1 (ZBP1) as an emerging innate immune sensor that converts genomic stress into potent antitumor immunity.

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on.

A new study from a team including University of Nebraska–Lincoln researchers is the first to show metabolites produced by certain bacteria in the gut can positively impact the body's immune response to cancer.

arXiv:2607.07261v1 Announce Type: new Abstract: Chimeric Antigen Receptor (CAR) T cell therapy has emerged as a successful treatment for relapsed or refractory hematological malignancies, particularly for B cell Acute Lymphoblastic Leukemia (B ALL), where CD19 targeted therapies have achieved high initial remission rates. However, relapse after treatment remains a major clinical challenge, frequently associated with antigen escape mechanisms and the emergence of CD19$^-$ leukemic cells. Understanding the interaction between CAR T cells and antigen expression dynamics is, therefore, essential for improving therapeutic efficacy and long-term patient outcomes. In this work, we develop and comparatively analyze novel mathematical models describing CAR T immunotherapy and CD19 dynamics in leukemia. Our proposed framework combines compartmental ordinary differential equation (ODE) formulations as well as partial differential equation (PDE) systems. Both methods are able to capture the

Gastrointestinal side effects are among the most important issues to address with patients starting on immune checkpoint inhibitors.

Conventional TIL therapy, clinically validatedrecently with the U.S. Food and Drug Administration approval of lifileucel for advanced melanoma,stillfaces substantial hurdles.

The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.

Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others.

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in the tumor microenvironment.

The ERC (European Research Council) Proof of Concept grant awarded to Alexandre Detappe (Gustave Roussy/Institut Strauss/Université Paris-Saclay/Inserm) will fund the Nano-BITE project, which aims to improve the ability of the immune system to fight solid tumors through nanomedicine.

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that an artificial intelligence (AI)-based analysis of tumor biopsies can predict responses to immunotherapy in a study of patients with rare cancers, published in the Journal for ImmunoTherapy of Cancer.

Immune checkpoint blockade (ICB) has reshaped the treatment landscape for advanced hepatocellular carcinoma (HCC), offering new hope where few options existed.

A research team at the University of Turku in Finland has developed a reliable laboratory model to study BAP1-deficient melanomas, which are a rare type of melanoma that evade the immune system once they have metastasized and are universally resistant to current state-of-the-art immunotherapies. The tool could change how therapies are developed for aggressive melanomas that currently have almost no effective treatment options.

Patients with locally advanced cervical cancer who receive dual checkpoint blockade before standard chemoradiation have high 3-year survival, but outcomes are poorer for those with ‘cold’ tumors.

Researchers found that a rare liver cancer evades immunotherapy by luring immune T cells away from the tumor and trapping them in nearby fibrous tissue. An FDA-approved drug called AMD3100 freed those T cells to attack the cancer, significantly improving the effectiveness of immunotherapy in tumor samples.

A pilot study from Karolinska Institutet shows that immunotherapy may enable stimulation of egg maturation in women with autoimmune POI (premature ovarian insufficiency) – a condition that usually leads to infertility.

Traditional cancer treatments like chemotherapy and radiotherapy can induce immunogenic cell death (ICD), but their efficacy is often limited by drug resistance, severe off-target toxicity, and immune-related adverse events.

Oral immunotherapy with pasteurized egg may reduce the risk for serious reactions from accidental exposure and offer a feasible alternative to strict avoidance in young children with egg allergy.

Physician-scientist Theodore Scott Nowicki, MD, PhD, an assistant professor in the department of pediatrics hematology/oncology and microbiology, immunology, & molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded the Hero Grant from MIB Agents, a nonprofit organization dedicated to improving outcomes for children and young adults with osteosarcoma.

Liver transplantation remains one of the most powerful curative options for hepatocellular carcinoma (HCC) because it removes both the tumor and the diseased liver.

Creatine, the organic acid that is popularly taken as a supplement by athletes and bodybuilders, supercharges a critical class of immune cells that activate and prepare the body’s key cancer-fighters, according to new UCLA research.

A study from the University of Calgary shows that removing a single gene makes colon cancer cells a target for immunotherapy - a fundamental breakthrough.

A new study led by researchers at The University of Texas MD Anderson Cancer Center demonstrated that pre-operative radiation therapy for brain metastases not only targets tumor cells directly but also can activate immune pathways that can make tumors more receptive to immunotherapy.

A type of white blood cell in the immune system, known as neutrophils, can make cancer immunotherapy less effective. This is shown in a new study from Karolinska Institutet published in the journal Immunity.

A comprehensive review led by Associate Researcher Linnan Zhu and Academician Zemin Zhang at Biomedical Pioneering Innovation Center (BIOPIC), Peking University, China, and Chongqing Medical University, China, was published in Volume 2, article number 27 of the journal Immunity & Inflammation on June 05, 2026.

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has accepted for review Genentech's supplemental Biologic License Application for their immunotherapy drug atezolizumab (Tecentriq®) for the treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

Malignant tumors remain a major threat to human health, with conventional therapies and first-generation immune checkpoint inhibitors (ICIs) facing limitations like drug resistance and low response rates.

Starting egg oral immunotherapy at low in-clinic doses and increasing them slowly is associated with better tolerance and may help patients with egg allergy reintroduce egg into their diets.

The study adds to growing evidence that immunotherapy and chemoembolization prolong progression-free survival.

Early peanut oral immunotherapy may confer lasting immune benefits, with most young patients continuing to consume peanuts years later and only a few reporting allergic reactions.

Immune checkpoint therapy, a type of cancer immunotherapy that helps the immune system recognize and attack tumors, has transformed cancer treatment.

Preventive house dust mite sublingual immunotherapy in sensitized, symptom-free preschoolers may safely induce blocking antibodies, reduce allergic responses, and limit new sensitizations.

Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have revolutionized the treatment of many types of tumor.

arXiv:2605.25050v1 Announce Type: new Abstract: Integrating multimodal datasets in clinical oncology is frequently hindered by high dimensionality and blockwise missingness, where entire data sources are unavailable for specific patient subsets. Standard survival models often struggle with these gaps, leading to biased results or patient exclusion. We introduce Multimodality Stacking with Blockwise missing values (MSB), a late-fusion framework for survival analysis that independently models modality-specific features before aggregating predictions via a cross-validated stacking meta-learner. MSB was validated on the PIONeeR study (n=443 patients, 378 biomarkers across eight heterogeneous sources) to predict progression-free survival in advanced non-small cell lung cancer patients receiving immunotherapy. MSB yielded higher predictive performance (C-index) than baseline algorithms. Improvements varied by baseline strength: linear models showed a 15.9% increase (p

arXiv:2605.25050v1 Announce Type: cross Abstract: Integrating multimodal datasets in clinical oncology is frequently hindered by high dimensionality and blockwise missingness, where entire data sources are unavailable for specific patient subsets. Standard survival models often struggle with these gaps, leading to biased results or patient exclusion. We introduce Multimodality Stacking with Blockwise missing values (MSB), a late-fusion framework for survival analysis that independently models modality-specific features before aggregating predictions via a cross-validated stacking meta-learner. MSB was validated on the PIONeeR study (n=443 patients, 378 biomarkers across eight heterogeneous sources) to predict progression-free survival in advanced non-small cell lung cancer patients receiving immunotherapy. MSB yielded higher predictive performance (C-index) than baseline algorithms. Improvements varied by baseline strength: linear models showed a 15.9% increase (p

arXiv:2605.25050v1 Announce Type: cross Abstract: Integrating multimodal datasets in clinical oncology is frequently hindered by high dimensionality and blockwise missingness, where entire data sources are unavailable for specific patient subsets. Standard survival models often struggle with these gaps, leading to biased results or patient exclusion. We introduce Multimodality Stacking with Blockwise missing values (MSB), a late-fusion framework for survival analysis that independently models modality-specific features before aggregating predictions via a cross-validated stacking meta-learner. MSB was validated on the PIONeeR study (n=443 patients, 378 biomarkers across eight heterogeneous sources) to predict progression-free survival in advanced non-small cell lung cancer patients receiving immunotherapy. MSB yielded higher predictive performance (C-index) than baseline algorithms. Improvements varied by baseline strength: linear models showed a 15.9% increase (p

Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature within tumors that can help identify patients with metastatic castration-resistant prostate cancer (mCRPC) who are more likely to experience lasting benefits from combined immunotherapy treatment.

Researchers from The University of Osaka find that only a small fraction of T cells may drive the robust anti-cancer response seen in breakthrough multiple myeloma immunotherapy.

Conventional immune checkpoint inhibitors, such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, can reinvigorate T cells but typically benefit less than 30% of patients.

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.)

Immunotherapy could be used to treat depression, early trial suggests  The GuardianPilot trial suggests anti-inflammatory drug could help difficult-to-treat depression  Medical XpressExperts uncover anti-inflammatory drug that could help millions of Brits who suffer from depression  The IndependentDepression ‘cured’ in half of patients taking arthritis drug given to thousands  The SunAnti-Inflammatory Drug Could Help Some People with Depression  Inside Precision Medicine

Immunotherapy could be used to treat depression, early trial suggests  The GuardianPilot trial suggests anti-inflammatory drug could help difficult-to-treat depression  Medical XpressExperts uncover anti-inflammatory drug that could help millions of Brits who suffer from depression  The IndependentDepression ‘cured’ in half of patients taking arthritis drug given to thousands  The SunAnti-Inflammatory Drug Could Help Some People with Depression  Inside Precision Medicine

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.

As tumors outgrow their blood and nutrient supplies, or respond to treatments like chemotherapy and radiotherapy, individual cancer cells die, exposing their internal scaffolds.

Cancer immunotherapy works by mobilizing the body's own immune system to recognize and destroy malignant cells.

Researchers at the Francis Crick Institute have revealed that sensory nerve signals interfere with the immune system's response to lung cancer.

NICE has recommended durvalumab for NHS use in England as part of perioperative treatment for adults with resectable gastric or gastro-oesophageal junction adenocarcinoma.

Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB).

Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater precision while remodeling the tumor microenvironment. The review highlights how nano-immunotherapy could boost immune activation, improve checkpoint-blockade responses, and support more personalized cancer treatment, although safety, scalability, and clinical translation challenges remain.

A Swedish randomized trial found that slow up-dosing peanut oral immunotherapy with a low maintenance dose helped 82% of preschool children achieve sustained peanut tolerance after three years. The approach proved safer than conventional protocols, with severe reactions uncommon and strong family adherence throughout treatment.

In this webinar, Joseph Shultz (VP of technical development and manufacturing, Ottimo Pharma) and Imroz Ghangas (VP of commercial sales, Asimov) discuss strategies for achieving high-performing clonal titers and advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. The post From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies appeared first on GEN - Genetic Engineering and Biotechnology News.

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have identified a promising new strategy to overcome resistance to immunotherapy in colorectal cancer, one of the leading causes of cancer-related deaths worldwide.

Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy  Fox NewsBreakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years  SciTechDailyPre-Surgery Immunotherapy Shows Promising Results in Bowel Cancer  The Indian PractitionerImmunotherapy Trial Shows 100 Percent Success Rate for Bowel Cancer Patients  HarianBasis.co

Patients remain cancer-free nearly 3 years after receiving experimental immunotherapy  Fox NewsBreakthrough Bowel Cancer Trial Leaves Patients Cancer-Free for Nearly 3 Years  SciTechDailyPre-Surgery Immunotherapy Shows Promising Results in Bowel Cancer  The Indian PractitionerImmunotherapy Trial Shows 100 Percent Success Rate for Bowel Cancer Patients  HarianBasis.co

arXiv:2604.24360v1 Announce Type: new Abstract: Immune checkpoint inhibitor--based therapies often produce heterogeneous survival responses, including early risk, delayed treatment benefit, and durable long-term survival in a subset of patients. In these settings, conventional summary measures such as the hazard ratio may not adequately describe how treatment effects evolve over follow-up. We propose a milestone-based framework that separates long-term survival beyond a clinically meaningful time point from earlier outcomes and provides a practical way to characterize patient heterogeneity in treatment response. The framework summarizes treatment differences through milestone survival probabilities and, among patients who do not reach the milestone, characterizes short-term treatment ordering over time using a tau-based summary that helps identify hazard reversal. We illustrate the approach using reconstructed individual-level data from three landmark phase III trials: CheckMate~067,

A small Italian study suggests a way to safely reduce gastrectomy rates in microsatellite instability-high disease.

In the context of Alzheimer's disease, the data for anti-amyloid immunotherapies, the most recent of which do effectively clear the aggregation of amyloid-β in the brain, is not compelling. Clinical trials and following studies show minimal to no benefit to patients even at earlier stages of the condition. There is some hope in the research and development community, where the amyloid cascade hypothesis remains dominant, that moving to even earlier deployment of these therapies might prevent the emergence of the condition, but the data obtained to date does not inspire optimism on this front. Other directions are much needed, perhaps restoration of cerebrospinal fluid drainage, for example, or more of a focus on chronic inflammation in brain tissue. Alzheimer's disease is a neurodegenerative disorder and […]

Omalizumab, alone or with allergen immunotherapy for house dust mites, may reduce daily use of inhaled corticosteroids in patients with house dust mite-sensitized mild-to-moderate allergic asthma.

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows.

A new UCLA Health Jonsson Comprehensive Cancer Center study suggests that the way immune cells are organized inside melanoma tumors may help researchers better understand which patients will benefit from combination immunotherapy after standard anti-PD-1 treatment stops working - and which may not.

An artificial intelligence (AI) model developed by researchers at The University of Texas MD Anderson Cancer Center demonstrated the ability to accurately predict responses to immunotherapy for patients with metastatic non-small cell lung cancer (NSCLC).

Path-IO accurately stratified immunotherapy outcomes for patients with metastatic non-small cell lung cancer (NSCLC). The model is validated across international real-world cohorts and a Phase III randomized clinical trial. The post AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model appeared first on GEN - Genetic Engineering and Biotechnology News.

Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in patients who experienced co-occurring myositis and myasthenia gravis, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

Injecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery, according to research from a phase I clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

Patients with a specific type of bowel cancer who were treated with a short course of immunotherapy before surgery instead of post-op chemotherapy have remained cancer-free after almost three years of follow-up, according to new results from the NEOPRISM-CRC clinical trial led by a team from UCL and UCLH.

A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.

A phase 2 study evaluates the safety and efficacy of brentuximab vedotin and nivolumab plus chemotherapy in patients with early-stage classical Hodgkin lymphoma.

SUNDAY, April 19, 2026 — Immunotherapy has largely failed as a treatment for cancer of the pancreas, and researchers have zeroed in on a key reason.Pancreatic tumors reprogram immune cells that normally shut down tumor-killing cells, according to a...

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the deadliest cancers worldwide.

The Scottish Medicines Consortium has accepted pembrolizumab with chemoradiotherapy for high-risk, locally advanced cervical cancer in Scotland.

'It's incredible, like science fiction': How a new wave of immunotherapy is eliminating cancers  BBC

'It's incredible, like science fiction': How a new wave of immunotherapy is eliminating cancers  BBC

Macrophages, much like Alice of "Alice in Wonderland," recognize and consume tumor cells that display "eat me" surface markers.

Researchers at Oregon Health & Science University have uncovered a key reason why immunotherapy has largely failed in pancreatic cancer - and identified a promising strategy to overcome that resistance.

A UAB research team defines the criteria that CAR immunotherapies for neurodegenerative diseases must meet to advance both conceptually and in trials, which are still at a very preliminary stage, in a review study published in the journal Trends in Pharmacological Sciences.

arXiv:2604.05478v1 Announce Type: new Abstract: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only marginal

arXiv:2604.05478v1 Announce Type: cross Abstract: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy; yet substantial proportion of patients exhibit intrinsic or acquired resistance, making accurate pre-treatment response prediction a critical unmet need. Transcriptomics-based biomarkers derived from bulk and single-cell RNA sequencing (scRNA-seq) offer a promising avenue for capturing tumour-immune interactions, yet the cross-cohort generalisability of existing prediction models remains unclear.We systematically benchmark nine state-of-the-art transcriptomic ICI response predictors, five bulk RNA-seq-based models (COMPASS, IRNet, NetBio, IKCScore, and TNBC-ICI) and four scRNA-seq-based models (PRECISE, DeepGeneX, Tres and scCURE), using publicly available independent datasets unseen during model development. Overall, predictive performance was modest: bulk RNA-seq models performed at or near chance level across most cohorts, while scRNA-seq models showed only

A new tool makes it possible to screen millions of tiny protein fragments and select those that can be recognized by the immune system. The CIC biomaGUNE Center for Cooperative Research in Biomaterials has developed epiGPTope, a system that uses machine learning to generate and classify epitopes, in collaboration with the company Multiverse Computing.

A new metabolic mechanism describes how tumors disable immune “gatekeeper” in the presence of cancer. Study shows that boosting mitochondrial function in dendritic cells enhances antitumor immune activity and strengthens the efficacy immunotherapies. The post Immunotherapy Enhanced by Restoring Mitochondrial Function in Dendritic Cells appeared first on GEN - Genetic Engineering and Biotechnology News.

St. Jude Children's Research Hospital scientists have discovered how tumors disable immune "gatekeeper" cells that alert the rest of the immune system to the presence of cancer - and how restoring their energy production can improve immunotherapy. Dendritic cells activate the cytotoxic immune cells that destroy cancer.

Researchers developed novel, first-in-class drugs that inhibit both HIF-1 and HIF-2 and which, combined with immunotherapy, eliminated breast, colorectal, melanoma, and prostate tumors in mice, suggesting that the drugs could eventually be used to treat a broad range of cancers in humans. The post Combining Novel Dual HIF Inhibitors with Immunotherapy Erases Multiple Tumor Types in Mice appeared first on GEN - Genetic Engineering and Biotechnology News.

Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be "master regulators" of cancer progression.

Immune-related pruritus may be observed in a quarter of patients with metastatic melanoma treated with immune checkpoint inhibitors.

arXiv:2604.00739v1 Announce Type: new Abstract: Datasets used in immunotherapy response prediction are typically small in size, as well as diverse in cancer type, drug administered, and sequencer used. Models often drop in performance when tested on patient cohorts that are not included in the training process. Recent work has shown that transformer-based models along with self-supervised learning show better generalisation performance than threshold-based biomarkers, but is still suboptimal. We present BioCOMPASS, an extension of a transformer-based model called COMPASS, that integrates biomarkers and treatment information to further improve its generalisability. Instead of feeding biomarker data as input, we built loss components to align them with the model's intermediate representations. We found that components such as treatment gating and pathway consistency loss improved generalisability when evaluated with Leave-one-cohort-out, Leave-one-cancer-type-out and

Some studies have suggested that morning is the optimal time for immunotherapy, but a new analysis of patients with lung cancer begs to differ.

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called

Advanced gastric cancer remains one of the deadliest malignancies, with a 5-year overall survival rate below 10%.

A new study from researchers at the Alliance for Clinical Trials in Oncology (Alliance) shows that patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR) had significantly better outcomes when the immunotherapy drug atezolizumab (Tecentriq®) was added to standard chemotherapy after surgery.

A new approach engineers immune cells to recognize byproducts of cancer cells to trigger migration toward solid tumors.The method differs from CAR T-cell therapy, which recognizes proteins tethered to the surface of the cancer cell.   The post Immunotherapy for Solid Tumors Enhanced by Metabolite-Sensing Receptors appeared first on GEN - Genetic Engineering and Biotechnology News.

Thymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThymic health consequences in adults  NatureLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical XpressThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanClinical briefs for Thursday, March 19  McKnight's Long-Term Care News

Thymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThymic health consequences in adults  NatureLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical XpressThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanClinical briefs for Thursday, March 19  McKnight's Long-Term Care News

Thymic health and immunotherapy outcomes in patients with cancer  NatureThymic health consequences in adults  NatureThymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical Xpress

Thymic health and immunotherapy outcomes in patients with cancer  NatureThymic health consequences in adults  NatureThymus May Be Critical for Longevity and Cancer Immunotherapy Response  Harvard Medical SchoolThis overlooked organ may be more vital for longevity than scientists realized  Scientific AmericanLong dismissed in adult health, the thymus may be critical for longevity and cancer treatment  Medical Xpress

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well to immunotherapy.

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including common variants such as cancers of the breast, liver, and colon.